Bioxodes

Focus: Bioxodes is a small Belgian biotech focused on thrombosis therapies in cardiovascular disease, operating with 51-200 employees since 2013.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Employees

51-200

Open Jobs

About Bioxodes

AI assessmentNot Hiring

No open roles listed right now. Follow Bioxodes to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Ir-CPI - Dose 1

Healthy

PHASE_1

Clinical Trials (1)

NCT04653766A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ir-CPI in Healthy Male Subjects

Phase 1

Help build intelligence for Bioxodes

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage pipeline with Phase 2 data in intracerebral hemorrhage—a high-unmet-need indication with limited competitive options
Small, focused team (51-200 employees) allows direct impact on drug development decisions and visibility into clinical strategy
Public company status provides regulatory transparency and potential equity upside as pipeline advances

Watch Out For

Only 2 active clinical trials and no Phase 3 programs suggest limited near-term revenue generation and commercial scale
Minimal hiring activity (2 open roles) indicates constrained growth trajectory and limited career mobility within the organization

Generated by Claude from Bioxodes's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Ir-CPI

Intracerebral Hemorrhage

PHASE_2

Clinical Trials (1)

NCT05970224A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2013

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo